keyword
MENU ▼
Read by QxMD icon Read
search

Free psa

keyword
https://www.readbyqxmd.com/read/29671075/stereotactic-body-radiotherapy-for-castration-sensitive-prostate-cancer-bone-oligometastases
#1
Giuseppe Fanetti, Giulia Marvaso, Delia Ciardo, Annaisabel Rese, Rosalinda Ricotti, Elena Rondi, Stefania Comi, Federica Cattani, Dario Zerini, Cristiana Fodor, Ottavio de Cobelli, Roberto Orecchia, Barbara A Jereczek-Fossa
To evaluate outcome in patients treated with stereotactic body radiotherapy (SBRT) on bone oligometastases from castration-sensitive prostate cancer after primary treatment. We retrospectively collected data of patients with less than five lesions at time of SBRT and hormone-naïve disease at the first extra-regional localization, treated between 03/2012 and 11/2016. Prostate-specific antigen (PSA) was measured every 3 months after SBRT. Imaging was performed in case of progression. Survival analysis was performed with Kaplan-Meier (log-rank test) approach...
April 18, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29661587/medium-term-follow-up-of-vascular-targeted-photodynamic-therapy-of-localized-prostate-cancer-using-tookad-soluble-wst-11-phase-ii-trials
#2
A Noweski, A Roosen, S Lebdai, E Barret, M Emberton, F Benzaghou, M Apfelbeck, B Gaillac, C Gratzke, C Stief, A R Azzouzi
BACKGROUND AND OBJECTIVE: To assess the medium-term tumor control in patients with localized prostate cancer (PCa) treated with vascular-targeted photodynamic (VTP) therapy with TOOKAD Soluble WST11 (VTP) and to assess the medium-term tolerability of the treatment. DESIGN, SETTING, PARTICIPANTS, AND INTERVENTION: During the clinical phase II studies, 68 patients were treated with VTP under optimal treatment conditions (WST11 at 4mg/kg, light energy at 200J/cm, and a light density index ≥1) and have been included in a 3...
April 13, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29651796/oncological-impact-of-neoadjuvant-hormonal-therapy-on-permanent-iodine-125-seed-brachytherapy-in-patients-with-low-and-intermediate-risk-prostate-cancer
#3
Atsushi Takamoto, Ryuta Tanimoto, Kensuke Bekku, Motoo Araki, Takuya Sadahira, Koichiro Wada, Shin Ebara, Norihisa Katayama, Hiroyuki Yanai, Yasutomo Nasu
OBJECTIVES: To determine whether neoadjuvant hormonal therapy improves oncological outcomes of patients with localized prostate cancer treated with permanent brachytherapy. METHODS: Between January 2004 and November 2014, 564 patients underwent transperineal ultrasonography-guided permanent iodine-125 seed brachytherapy. We retrospectively analyzed low- or intermediate-risk prostate cancer based on the National Comprehensive Cancer Network guidelines. The clinical variables were evaluated for influence on biochemical recurrence-free survival, progression-free survival, cancer-specific survival and overall survival...
April 12, 2018: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/29651712/prognostic-impact-of-nodal-relapse-in-definitive-prostate-only-irradiation
#4
Mauro Loi, Luca Incrocci, Isacco Desideri, Pierluigi Bonomo, Beatrice Detti, Gabriele Simontacchi, Daniela Greto, Emanuela Olmetto, Giulio Francolini, Icro Meattini, Lorenzo Livi
BACKGROUND: Whole pelvic irradiation in prostate cancer patients might prevent metastatic spread of cancer cells through lymphatic drainages in patients eligible for definitive radiotherapy, but its use has declined in the last decades in favor of prostate-only irradiation (POI). The aim of our study is to assess the incidence of pelvic lymph nodal relapse and outcome in prostate cancer patients receiving POI. MATERIALS AND METHODS: Data from 207 consecutive patients were collected...
April 12, 2018: La Radiologia Medica
https://www.readbyqxmd.com/read/29650035/image-guided-radiotherapy-reduces-the-risk-of-under-dosing-high-risk-prostate-cancer-extra-capsular-disease-and-improves-biochemical-control
#5
Per Munck Af Rosenschold, Michael J Zelefsky, Aditya P Apte, Andrew Jackson, Jung Hun Oh, Elliot Shulman, Neil Desai, Margie Hunt, Pirus Ghadjar, Ellen Yorke, Joseph O Deasy
BACKGROUND: To determine if reduced dose delivery uncertainty is associated with daily image-guidance (IG) and Prostate Specific Antigen Relapse Free Survival (PRFS) in intensity-modulated radiotherapy (IMRT) of high-risk prostate cancer (PCa). METHODS: Planning data for consecutive PCa patients treated with IMRT (n = 67) and IG-IMRT (n = 35) was retrieved. Using computer simulations of setup errors, we estimated the patient-specific uncertainty in accumulated treatment dose distributions for the prostate and for posterolateral aspects of the gland that are at highest risk for extra-capsular disease...
April 12, 2018: Radiation Oncology
https://www.readbyqxmd.com/read/29629665/overall-and-multiphasic-findings-of-the-prostate-lung-colorectal-and-ovarian-plco-randomized-cancer-screening-trial
#6
Philip C Prorok, Patrick Wright, Thomas R Riley, Barnett S Kramer, Christine D Berg, John K Gohagan
BACKGROUND: Screening tests are typically evaluated for a single disease, but multiple tests for multiple diseases are performed in practice. The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial assessed testing for four cancers simultaneously and can be viewed as a multiphasic cancer intervention. This paper presents overall and multiphasic findings of this trial. METHODS: The PLCO trial was a randomized multi-center trial conducted at ten screening centers in the US...
April 9, 2018: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/29627830/prediction-of-biochemical-recurrence-following-radiotherapy-among-patients-with-persistent-psa-after-radical-prostatectomy-a-single-center-experience
#7
Chenhui Xiang, Xiaoyong Liu, Shenglong Chen, Pengqiao Wang
Radiotherapy (RT) is applied in prostate cancer patients with a biochemical recurrence (BcR) after radical prostatectomy (RP). However, for the patients with persistent PSA but not undergoing the process of BcR, it remains unknown whether the application of RT can exempt them from the upcoming BcR. In this study, we identified 104 patients treated with RP who had persistent PSA level >0.1 but ≤0.2 ng/mL at 6-8 weeks after RP, of which 52 were treated with postoperative RT. Overall, 51 patients experienced BcR, among which 20 patients were treated with postoperative RT...
April 6, 2018: Urologia Internationalis
https://www.readbyqxmd.com/read/29627197/time-to-event-outcomes-in-men-with-nonmetastatic-castrate-resistant-prostate-cancer-a-systematic-literature-review-and-pooling-of-individual-participant-data
#8
REVIEW
Markus Aly, Mahmoud Hashim, Bart Heeg, Johan Liwing, Amy Leval, Maneesha Mehra, Joe Lawson, Sabine D Brookman-May, Olof Akre
CONTEXT: Until recently, there has been a lack of evidence-based treatment alternatives in men with nonmetastatic castrate-resistant prostate cancer (NM-CRPC). However, new evidence-based treatment alternatives are emerging. OBJECTIVE: We aimed to describe time-to-event outcomes in NM-CRPC patients based on evidence from both prospective and retrospective studies. Second, we aimed to describe predictors of these outcomes in the same patient population. EVIDENCE ACQUISITION: A systematic review was conducted to identify clinical studies (both prospective and retrospective) in NM-CRPC patients...
April 4, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29625755/-99m-technetium-based-prostate-specific-membrane-antigen-radioguided-surgery-in-recurrent-prostate-cancer
#9
Tobias Maurer, Stephanie Robu, Margret Schottelius, Kristina Schwamborn, Isabel Rauscher, Nynke S van den Berg, Fijs W B van Leeuwen, Bernhard Haller, Thomas Horn, Matthias M Heck, Jürgen E Gschwend, Markus Schwaiger, Hans-Jürgen Wester, Matthias Eiber
BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) can visualize metastatic lesions in recurrent prostate cancer (PC). However, reliable identification of small and/or atypically localized lesions during salvage surgery procedures is challenging. OBJECTIVE: To describe the technique, feasibility, and short-term outcomes of99m Technetium (99m Tc)-based PSMA-radioguided surgery (99m Tc-PSMA-RGS) for removal of recurrent PC lesions...
April 3, 2018: European Urology
https://www.readbyqxmd.com/read/29624919/increased-cytokines-in-cystic-fibrosis-patients-upper-airways-during-a-new-p-aeruginosa-colonization
#10
Anke Jaudszus, Christin Arnold, Julia Hentschel, Kerstin Hünniger, Michael Baier, Jochen G Mainz
OBJECTIVES: Previously, we found linkages of inflammatory mediator levels in CF upper airways (UAW) sampled by nasal lavage (NL) to disease severity and to chronic pathogen colonization such as Pseudomonas aeruginosa (PsA). Here, we assess UAW cytokine dynamics in CF patients with a new PsA colonization. METHODS: We measured cytokines in 149 longitudinally obtained NL samples from 34 CF patients. Cytokine concentrations determined prior to, at the time of de novo PsA detection in either UAW or lower airways (LAW), and in a subsequent PsA free period in newly colonized patients (PsA-new/n = 7) were compared to levels of not- (PsA-free/n = 13) and chronically colonized patients (PsA-chron/n = 14)...
April 6, 2018: Pediatric Pulmonology
https://www.readbyqxmd.com/read/29624463/phase-iii-intergroup-trial-of-adjuvant-androgen-deprivation-with-or-without-mitoxantrone-plus-prednisone-in-patients-with-high-risk-prostate-cancer-after-radical-prostatectomy-swog-s9921
#11
Maha Hussain, Catherine M Tangen, Ian M Thompson, Gregory P Swanson, David P Wood, Wael Sakr, Nancy A Dawson, Naomi B Haas, Thomas W Flaig, Tanya B Dorff, Daniel W Lin, E David Crawford, David I Quinn, Nicholas J Vogelzang, L Michael Glode
Purpose Patients with high-risk prostate cancer after radical prostatectomy are at risk for death. Adjuvant androgen-deprivation therapy (ADT) may reduce this risk. We hypothesized that the addition of mitoxantrone and prednisone (MP) to adjuvant ADT could reduce mortality compared with adjuvant ADT alone. Methods Eligible patients had cT1-3N0 prostate cancer with one or more high-risk factors after radical prostatectomy (Gleason score [GS] ≥ 8; pT3b, pT4, or pN+ disease; GS 7 and positive margins; or preoperative prostate-specific antigen [PSA] > 15 ng/mL, biopsy GS score > 7, or PSA > 10 ng/mL plus biopsy GS > 6...
April 6, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29608544/treatment-optimization-for-hepatocellular-carcinoma-in-elderly-patients-in-a-japanese-nationwide-cohort
#12
Masaki Kaibori, Kengo Yoshii, Kiyoshi Hasegawa, Asao Ogawa, Shoji Kubo, Ryosuke Tateishi, Namiki Izumi, Masumi Kadoya, Masatoshi Kudo, Takashi Kumada, Michiie Sakamoto, Osamu Nakashima, Yutaka Matsuyama, Tadatoshi Takayama, Norihiro Kokudo
OBJECTIVE: We reviewed nationwide follow-up data to determine outcomes of different treatments for early-stage hepatocellular carcinoma (HCC) in elderly patients. SUMMARY BACKGROUND DATA: Outcomes of early-stage HCC treatments in elderly patients have not been prospectively compared. METHODS: We included 6490 HCC patients, aged ≥75 years at treatment, who underwent curative hepatic resection (HR, n = 2020), radiofrequency ablation (RFA, n = 1888), microwave ablation (MWA, n = 193), or transcatheter arterial chemoembolization (TACE, n = 2389), and compared their characteristics and survival...
March 30, 2018: Annals of Surgery
https://www.readbyqxmd.com/read/29607601/ldr-brachytherapy-for-the-treatment-of-localised-prostate-cancer-in-men-with-a-high-risk-of-disease-relapse
#13
Robert Laing, Jennifer Uribe, Santiago Uribe-Lewis, Julian Money-Kyrle, Carla Perna, Stylianos Chintzoglou, Sara Khaksar, Stephen E M Langley
OBJECTIVES: To report clinical outcomes of Iodine-125 Low-Dose-Rate Prostate Brachytherapy (LDR-PB) as monotherapy or in combination with androgen deprivation therapy (ADT) and/or external beam radiotherapy (EBRT) in high-risk localised prostate cancer (PCa). PATIENTS AND METHODS: Analysis of clinical outcomes from a prospective cohort of patients treated with LDR-PB alone or combination treatment in a single institution. Men with a high risk of disease relapse were identified by the National Institute for Healthcare Excellence (NICE) criteria or by the National Comprehensive Cancer Network (NCCN) criteria...
April 1, 2018: BJU International
https://www.readbyqxmd.com/read/29606109/neoadjuvant-degarelix-with-or-without-apalutamide-followed-by-radical-prostatectomy-for-intermediate-and-high-risk-prostate-cancer-arneo-a-randomized-double-blind-placebo-controlled-trial
#14
Lorenzo Tosco, Annouschka Laenen, Thomas Gevaert, Isabelle Salmon, Christine Decaestecker, Elai Davicioni, Christine Buerki, Frank Claessens, Johan Swinnen, Karolien Goffin, Raymond Oyen, Wouter Everaerts, Lisa Moris, Gert De Meerleer, Karin Haustermans, Steven Joniau
BACKGROUND: Recent retrospective data suggest that neoadjuvant androgen deprivation therapy can improve the prognosis of high-risk prostate cancer (PCa) patients. Novel androgen receptor pathway inhibitors are nowadays available for treatment of metastatic PCa and these compounds are promising for early stage disease. Apalutamide is a pure androgen antagonist with a very high affinity with the androgen receptor. The combination of apalutamide with degarelix, an LHRH antagonist, could increase the efficacy compared to degarelix alone...
April 2, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29599353/long-term-results-of-external-beam-radiotherapy-for-prostate-cancer-with-prostate-specific-antigen-of-more-than-50-ng-ml-and-without-evidence-of-lymph-node-or-distant-metastasis
#15
Rei Umezawa, Koji Inaba, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Satoshi Shima, Keisuke Tsuchida, Tairo Kashihara, Kazuma Kobayashi, Ken Harada, Kana Takahashi, Naoya Murakami, Yoshinori Ito, Hiroshi Igaki, Keiichi Jingu, Jun Itami
BACKGROUND/AIM: To evaluate long-term treatment outcomes of external beam radiotherapy for prostate cancer with a pretreatment prostate-specific antigen (PSA) level of more than 50 ng/ml and without evidence of lymph node or distant metastasis. PATIENTS AND METHODS: Definitive radiotherapy of 66 Gy or 72 Gy in combination with androgen deprivation therapy (ADT) was performed. PSA relapse-free survival (PRFS), distant metastasis-free survival (DMFS), cause-specific survival (CSS), and overall survival (OS) were evaluated...
April 2018: Anticancer Research
https://www.readbyqxmd.com/read/29595681/value-of-free-total-prostate-specific-antigen-f-t-psa-ratios-for-prostate-cancer-detection-in-patients-with-total-serum-prostate-specific-antigen-between-4-and-10-ng-ml-a-meta-analysis
#16
Yan Huang, Zhen-Zhen Li, Ya-Liang Huang, Hong-Jun Song, You-Juan Wang
BACKGROUND: Prostate carcinoma is a common disease that occurs in men over 50 years old. Many studies have explored the effect of free/total prostate-specific antigen (f/t PSA) ratio in monitoring prostate cancer. We conducted a meta-analysis to identify the accuracy of the f/t PSA ratio in the diagnosis of prostate cancer in patients who have PSA levels of 4 to 10 ng/mL. METHODS: Databases searched included PubMed and OVID databases, from inception to March 2017, after a systematical review, sensitivity, specificity, and other measures of accuracy of the f/t PSA ratio in the diagnosis of prostate cancer were pooled...
March 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29595042/does-prostate-volume-have-an-impact-on-the-functional-and-oncological-results-of-retzius-sparing-robot-assisted-radical-prostatectomy
#17
Antonio Galfano, Daniele Panarello, Silvia Secco, Dario DI Trapani, Michele Barbieri, Giancarlo Napoli, Elena Strada, Giovanni Petralia, Aldo M Bocciardi
BACKGROUND: The objective of our study is to evaluate the effect of prostatic volume on the outcomes of Retzius-Sparing robot-assisted radical Prostatectomy (RSP). METHODS: All the consecutive patients undergoing RSP up to January 2015 were included. The series was divided into three groups (<40 g, 40-60 g, >60 g). Perioperative, oncological and functional data were prospectively recorded. Potency was defined as erections sufficient for penetration; continence as no pad or 1 safety liner...
March 28, 2018: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/29594023/active-surveillance-for-prostate-cancer-a-systematic-review-of-contemporary-worldwide-practices
#18
REVIEW
Netty Kinsella, Jozien Helleman, Sophie Bruinsma, Sigrid Carlsson, Declan Cahill, Christian Brown, Mieke Van Hemelrijck
In the last decade, active surveillance (AS) has emerged as an acceptable choice for low-risk prostate cancer (PC), however there is discordance amongst large AS cohort studies with respect to entry and monitoring protocols. We systematically reviewed worldwide AS practices in studies reporting ≥5 years follow-up. We searched PubMed and Medline 2000-now and identified 13 AS cohorts. Three key areas were identified: (I) patient selection; (II) monitoring protocols; (III) triggers for intervention-(I) all studies defined clinically localised PC diagnosis as T2b disease or less and most agreed on prostate-specific antigen (PSA) threshold (<10 µg/L) and Gleason score threshold (3+3)...
February 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/29590007/prospective-international-randomized-phase-ii-study-of-low-dose-abiraterone-with-food-versus-standard-dose-abiraterone-in-castration-resistant-prostate-cancer
#19
Russell Z Szmulewitz, Cody J Peer, Abiola Ibraheem, Elia Martinez, Mark F Kozloff, Bradley Carthon, R Donald Harvey, Paul Fishkin, Wei Peng Yong, Edmund Chiong, Chadi Nabhan, Theodore Karrison, William D Figg, Walter M Stadler, Mark J Ratain
Purpose Abiraterone acetate (AA) is a standard of care for metastatic castration-resistant prostate cancer (CRPC). Despite a large food effect, AA was administered under fasting conditions in its pivotal trials. We sought to test the hypothesis that low-dose AA (LOW; 250 mg with a low-fat meal) would have comparable activity to standard AA (STD; 1,000 mg fasting) in patients with CRPC. Patients and Methods Patients (n = 72) with progressive CRPC from seven institutions in the United States and Singapore were randomly assigned to STD or LOW...
March 28, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29581775/increased-paxillin-expression-in-prostate-cancer-is-associated-with-advanced-pathological-features-lymph-node-metastases-and-biochemical-recurrence
#20
Qing-Shui Zheng, Shao-Hao Chen, Yu-Peng Wu, Hui-Jun Chen, Hong Chen, Yong Wei, Xiao-Dong Li, Jin-Bei Huang, Xue-Yi Xue, Ning Xu
Purpose Paxillin regulates cell-cell adhesion, and altered Paxillin expression has been associated with human carcinogenesis. This study analyzed the association between Paxillin expression in prostate cancer (PCa) tissues with clinicopathological features, lymph node metastasis and biochemical PCa recurrence. Methods A total of 386 tissue specimens from PCa patients who received radical prostatectomy and 60 tissue specimens from benign prostatic hyperplasia (BPH) cases were collected to construct tissue microarrays, which were subsequently immunostained for Paxillin expression...
2018: Journal of Cancer
keyword
keyword
25554
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"